The shares of orphan drugmaker Raptor Pharmaceuticals (NASDAQ: RPTP) have been on a tear since the FDA approval of its nephropathic cystinosis drug Procysbi. Year to date, shares are up more than 140%, and investors heard more good news last week after the drug won approval in the EU. In the following video, from the Motley Fool's health-care show Market Checkup, analysts discuss what this decision means for Raptor investors.
What does this EU approval mean for Raptor?
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.